Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3


Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

© 2015 John Wiley & Sons Ltd
SUMMARY. Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7 001 000 cases) and Indonesia (3 187 000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden.
INTRODUCTION

Hepatitis C virus (HCV) infection is a global public health burden, causing an increasing level of liver-related morbidity and mortality due to the disease progression of an aging-prevalent population [1–6]. The HCV disease paradigm varies by country based on historical and present risk factors, screening programmes and treatment rates. Individual countries must consider appropriate country-specific prevention, diagnosis and treatment strategies to reduce the disease burden represented by HCV. Unfortunately, in many countries, there is a lack of robust epidemiological data upon which to base these strategies. Many studies have examined regional HCV infection rates [7–12], but they have typically focused on quantifying the anti-HCV prevalence. This study is a continuation of a project to quantify global HCV epidemiology in a systematic manner. The aim of this study was to develop consensus estimates, using the best available published and unpublished data, for the total number of viraemic infections [HCV ribonucleic acid (RNA) positive], the total number of viraemic-diagnosed individuals, the number of viraemic newly diagnosed, annual number of treated patients and the number of liver transplants attributed to HCV in each country. The countries were selected based on the availability of published data and the willingness to collaborate. Other countries are being analysed and will be published separately.

METHODOLOGY

A systematic review of the literature was conducted to identify studies reporting the total number of HCV cases diagnosed, treated and cured in each country of interest. The review encompassed all studies between January 1990 and December 2014. Indexed articles were found by searching PubMed and Embase. Nonindexed sources were identified through individual countries’ Ministry of Health websites and international agencies’ reports. In addition, an expert panel in each country provided proceedings of local conferences, unpublished data and data from large liver centres that could be extrapolated to the national level.

Face-to-face meetings were conducted to review findings and analyses with the expert panel. When no input data were available, analogues (data from countries with a similar healthcare practice and/or risk factors) or expert inputs were used. Ranges were chosen to capture uncertainty in inputs, with wider ranges implying greater uncertainty.

Viraemic infections represented current RNA-positive HCV or chronic HCV infections. The term viraemic was used throughout this study to highlight the presence of HCV virus. The term new infections was used for acute infections among immigrants entering the country. The term incidence was used for acute infections and not newly diagnosed. Care was taken to collect and list the year of the reported collection as the data were reported over a wide range of years. As shown in the next publication in this supplement [13], a modelling approach was used to estimate the HCV-infected populations (viraemic, diagnosed and treated) in 2014. Unless stated, population data were obtained from the United Nations’ (UN) population database by age, gender and five-year age-cohort [14].

The annual number of liver transplants was gathered from national or international databases and adjusted for the percentage attributed to HCV. The number of antibody-positive and RNA-positive diagnosed cases was gathered from national databases, use of analogues or expert panel input. It was explicitly stated when published or official data were not available. In countries where HCV was a notifiable infection and a reliable annual number of newly diagnosed cases were reported, the total of diagnosed cases was calculated by summing data from all years after taking into consideration the mortality among the diagnosed cases. In countries where the number of total and newly diagnosed cases was not available, expert panel input was used. Diagnosis rates from the known countries (analogues) were provided to the expert panel, and the panel selected one or more countries that had similar profiles. It was assumed that the viraemic rate among the diagnosed population was the same as the total infected population, and the same viraemic rate was used to estimate the number of viraemic-diagnosed individuals.

Two methods were used to estimate the total number of treated HCV-infected patients. In countries where reliable national data were available, the reported numbers were used. In other countries, the annual number of units of pegylated interferon (Peg-IFN) or ribavirin (RBV) sold, as reported by IMS Health [15], were converted to treated patients using the average number of units per patient. The average number of units per patient was calculated using the genotype distribution of the infected population (assumed the genotype distribution of the treated population was the same as the overall population), the duration of treatment for each genotype, the number of Peg-IFN or RBV units per week and the percentage of patients who completed their treatment (80% in most countries unless stated otherwise). The annual number of units was
adjusted using inputs from the expert panel to account for uses other than HCV as well as potential under-reporting.

RESULTS

Table 1 includes the results of the literature review for all 15 countries in this analysis, including estimates of antibody and viraemic prevalence, genotype distribution, viraemic diagnosis, annual treatment and liver transplants. The specific age and gender distribution of the viraemic-prevalent population for each country is shown in Fig. 1.

Estonia

HCV-infected population

HCV epidemiology data are sparse in Estonia. The prevalence of anti-HCV was estimated between 1.5% and 2.4%, in 2013, with a viraemic prevalence of 1.5% (1.1–1.9%) (expert consensus). The viraemic rate was estimated through expert consensus to be 76%. The age and gender distribution was estimated using annual notification data from 2000 to 2013 [16]. The notified population was aged to the year 2013, accounting for mortality and cured patients. Multiple genotype studies were available, with the most recent estimate chosen for consideration in the model [17].

Diagnosed

As of 2014, approximately 9600 viraemic cases were diagnosed (50%) (expert consensus). Annually, 190 viraemic cases are newly diagnosed [16].

Treated

In 2014, approximately 500 patients were treated for HCV. Of these, 34 ≥F3 patients were treated with boceprevir, 39 ≥F3 patients were treated with telaprevir, and the remainder of patients ≥F0 were treated with Peg-IFN/Riba [18].

Liver transplants

Data on the annual number of liver transplants and liver transplants attributable to HCV were available from the Transplantation Centre of Tartu University Hospital. Tartu University Hospital is the only hospital in Estonia where organ transplants are performed. In 2014, 10 liver transplants were performed, with four (40%) attributable to HCV.

Hungary

HCV-infected population

HCV epidemiology data are sparse in Hungary. The prevalence of anti-HCV was estimated at 0.70% (0.5–0.9%) based on expert consensus. A viraemic rate of 75%, provided by experts, was applied. The total viraemic population in 2014 was estimated at 52 000 (39 000–65 000) individuals, corresponding to a viraemic prevalence of 0.5% (0.4–0.7%). The age and gender distribution of the infected population was constructed using unpublished data from the Hungary treatment registry, which was provided through personal communication with experts (Makara 2015 personal communication). The genotype distribution in the prevalent population was estimated using data from both non-IDU and IDU sources. The non-IDU genotype distribution was based on data presented at the 8th International Symposium on Molecular Diagnostics [19], with adjustment based on expert consensus to the distribution of G1 and G3. The genotype distribution for IDU was based on personal communication with experts (Makara 2015 personal communication) and was proportionally combined with the non-IDU genotype distribution to calculate a weighted overall distribution for the prevalent population.

Diagnosed

Estimates of the diagnosed population were based upon expert consensus. There were an estimated 20 900 previously diagnosed cases in 2010 and 2100 newly diagnosed cases.

Treated

According to expert input, it was estimated that between 1000 and 1200 patients were treated annually.

Liver transplants

Liver transplant data were available through an international organ registry for the years 1993 to 2013 [20]. In 2013, there were 45 liver transplants performed in Hungary. According to expert consensus, the number of liver transplants jumped to 70 in 2014. Experts estimate that 30% of liver transplants per year are attributable to HCV.

Iceland

HCV-infected population

Overall prevalence of anti-HCV in 2014 was estimated at 0.4% (0.3–0.5%). Based on expert consensus, approximately 80% of HCV cases have been diagnosed in Iceland. The total number of surviving diagnosed anti-HCV cases, excluding previously treated and cured patients, is estimated at 1080 based on data from the Centre for Health Security and Infectious Disease Control, equivalent to approximately 1400 prevalent cases after adjustment for the undiagnosed population. A viraemic rate of 80% was applied, and the total viraemic population in 2014 was estimated at 1100 (880–1300) individuals after accounting for treated and cured patients, corresponding to a viraemic prevalence of 0.3% (0.3–0.4%). Data from the Centre for Health Security and Infectious Disease Control were used to determine the age and gender distribution based on demographic data collected from surviving diagnosed cases during 1986 to August 2014. The genotype
Table 1  Hepatitis C virus (HCV) epidemiology by country

<table>
<thead>
<tr>
<th>Country's Population (000)</th>
<th>Estonia</th>
<th>Hungary</th>
<th>Iceland</th>
<th>Indonesia</th>
<th>Iran</th>
<th>Japan</th>
<th>Latvia</th>
<th>Lebanon</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV Antibody Positive (000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cases</td>
<td>25</td>
<td>70</td>
<td>1.4</td>
<td>1848</td>
<td>275</td>
<td>1789</td>
<td>51</td>
<td>9.3</td>
</tr>
<tr>
<td>(19 - 31)</td>
<td>(52 - 87)</td>
<td>(1.1 - 1.6)</td>
<td>(277 - 3857)</td>
<td>(189 - 360)</td>
<td>(1443 - 2157)</td>
<td>(36 - 71)</td>
<td>(3.3 - 33)</td>
<td></td>
</tr>
<tr>
<td>Prevalence</td>
<td>2.0%</td>
<td>0.7%</td>
<td>0.4%</td>
<td>0.8%</td>
<td>0.4%</td>
<td>1.4%</td>
<td>2.4%</td>
<td>0.2%</td>
</tr>
<tr>
<td>(1.5% - 2.4%)</td>
<td>(0.5% - 0.9%)</td>
<td>(0.3% - 0.5%)</td>
<td>(0.1% - 1.7%)</td>
<td>(0.3% - 0.5%)</td>
<td>(1.1% - 1.7%)</td>
<td>(1.7% - 3.3%)</td>
<td>(0.1% - 0.7%)</td>
<td></td>
</tr>
<tr>
<td>Viremic Infections (000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Viremic Cases</td>
<td>19</td>
<td>52</td>
<td>1.1</td>
<td>1214</td>
<td>170</td>
<td>1252</td>
<td>39</td>
<td>7.9</td>
</tr>
<tr>
<td>(15 - 24)</td>
<td>(39 - 65)</td>
<td>(0.88 - 1.3)</td>
<td>(182 - 2534)</td>
<td>(117 - 223)</td>
<td>(1010 - 1510)</td>
<td>(26 - 50)</td>
<td>(2.8 - 28)</td>
<td></td>
</tr>
<tr>
<td>Viremic Prevalence</td>
<td>1.5%</td>
<td>0.5%</td>
<td>0.3%</td>
<td>0.5%</td>
<td>0.2%</td>
<td>1.0%</td>
<td>1.8%</td>
<td>0.2%</td>
</tr>
<tr>
<td>(1.1% - 1.9%)</td>
<td>(0.4% - 0.7%)</td>
<td>(0.3% - 0.4%)</td>
<td>(0.1% - 1.1%)</td>
<td>(0.2% - 0.3%)</td>
<td>(0.8% - 1.2%)</td>
<td>(1.2% - 2.4%)</td>
<td>(0.1% - 0.6%)</td>
<td></td>
</tr>
<tr>
<td>Viremic Rate (%)</td>
<td>76%</td>
<td>75%</td>
<td>80%</td>
<td>66%</td>
<td>62%</td>
<td>70%</td>
<td>71%</td>
<td>85%</td>
</tr>
<tr>
<td>Genotypes (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>1%</td>
<td>9%</td>
<td>41%</td>
<td>26%</td>
<td>40%</td>
<td></td>
<td>46%</td>
<td>25%</td>
</tr>
<tr>
<td>1b</td>
<td>72%</td>
<td>80%</td>
<td>2%</td>
<td>39%</td>
<td>12%</td>
<td>65%</td>
<td>4%</td>
<td>17%</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>2%</td>
<td>-</td>
<td>3%</td>
<td>1%</td>
<td></td>
<td>13%</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>73%</td>
<td>91%</td>
<td>43%</td>
<td>68%</td>
<td>53%</td>
<td>65%</td>
<td>64%</td>
<td>42%</td>
</tr>
<tr>
<td>2</td>
<td>3%</td>
<td>1%</td>
<td>1%</td>
<td>9%</td>
<td>1%</td>
<td>34%</td>
<td>4%</td>
<td>5%</td>
</tr>
<tr>
<td>3</td>
<td>24%</td>
<td>7%</td>
<td>55%</td>
<td>9%</td>
<td>28%</td>
<td></td>
<td>32%</td>
<td>8%</td>
</tr>
<tr>
<td>4</td>
<td>-</td>
<td>2%</td>
<td>1%</td>
<td>4%</td>
<td>1%</td>
<td></td>
<td>1%</td>
<td>46%</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10%</td>
<td>17%</td>
<td>1%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diagnosed (Viremic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cases</td>
<td>9600</td>
<td>20900</td>
<td>865</td>
<td>121000</td>
<td>60000</td>
<td>956000</td>
<td>17000</td>
<td>1600</td>
</tr>
<tr>
<td>Annual Newly Diagnosed</td>
<td>190</td>
<td>2100</td>
<td>60</td>
<td>12100</td>
<td>6000</td>
<td>8000</td>
<td>1300</td>
<td>160</td>
</tr>
<tr>
<td>Treated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Number Treated</td>
<td>500</td>
<td>1200</td>
<td>30</td>
<td>230</td>
<td>4500</td>
<td>26900</td>
<td>840</td>
<td>170</td>
</tr>
<tr>
<td>Liver Transplants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Liver Transplants</td>
<td>10</td>
<td>70</td>
<td>45</td>
<td>13</td>
<td>590</td>
<td>447</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>HCV Liver Transplants</td>
<td>4</td>
<td>21</td>
<td>2</td>
<td>0</td>
<td>94</td>
<td>219</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>% due to HCV</td>
<td>40%</td>
<td>30%</td>
<td>4%</td>
<td>0%</td>
<td>16%</td>
<td>49%</td>
<td>0%</td>
<td>6.7%</td>
</tr>
</tbody>
</table>

(continued)
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Country's Population (000)</th>
<th>Lithuania</th>
<th>Pakistan</th>
<th>Romania</th>
<th>Saudi Arabia</th>
<th>Slovenia</th>
<th>South Korea</th>
<th>UAE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV Antibody Positive (000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cases</td>
<td>51</td>
<td>8010</td>
<td>719</td>
<td>143</td>
<td>8.3</td>
<td>478</td>
<td>16</td>
</tr>
<tr>
<td>(31 - 70)</td>
<td>(5792 - 9920)</td>
<td>(637 - 800)</td>
<td>(116 - 368)</td>
<td>(6.2 - 10)</td>
<td>(376 - 621)</td>
<td>(14 - 18)</td>
<td></td>
</tr>
<tr>
<td>Prevalence</td>
<td>1.7%</td>
<td>4.8%</td>
<td>3.3%</td>
<td>0.7%</td>
<td>0.4%</td>
<td>1.0%</td>
<td>1.5%</td>
</tr>
<tr>
<td>(1.0% - 2.3%)</td>
<td>(3.5% - 5.9%)</td>
<td>(2.9% - 3.6%)</td>
<td>(0.6% - 1.9%)</td>
<td>(0.3% - 0.5%)</td>
<td>(0.8% - 1.3%)</td>
<td>(1.4% - 1.7%)</td>
<td></td>
</tr>
<tr>
<td>Viremic Infections (000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Viremic Cases</td>
<td>33</td>
<td>7001</td>
<td>611</td>
<td>100</td>
<td>6.5</td>
<td>268</td>
<td>11</td>
</tr>
<tr>
<td>(21 - 46)</td>
<td>(5062 - 8670)</td>
<td>(541 - 680)</td>
<td>(81 - 257)</td>
<td>(4.9 - 8.1)</td>
<td>(211 - 349)</td>
<td>(10 - 12)</td>
<td></td>
</tr>
<tr>
<td>Viremic Prevalence</td>
<td>1.1%</td>
<td>4.2%</td>
<td>2.8%</td>
<td>0.5%</td>
<td>0.3%</td>
<td>0.6%</td>
<td>1.0%</td>
</tr>
<tr>
<td>(0.7% - 1.5%)</td>
<td>(3.0% - 5.2%)</td>
<td>(2.5% - 3.1%)</td>
<td>(0.4% - 1.3%)</td>
<td>(0.2% - 0.4%)</td>
<td>(0.4% - 0.7%)</td>
<td>(0.9% - 1.1%)</td>
<td></td>
</tr>
<tr>
<td>Viremic Rate (%)</td>
<td>66%</td>
<td>87%</td>
<td>85%</td>
<td>70%</td>
<td>78%</td>
<td>56%</td>
<td>68%</td>
</tr>
<tr>
<td>Genotypes (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>2%</td>
<td>5%</td>
<td>5%</td>
<td>13%</td>
<td>14%</td>
<td>3%</td>
<td>8%</td>
</tr>
<tr>
<td>1b</td>
<td>69%</td>
<td>1%</td>
<td>93%</td>
<td>26%</td>
<td>23%</td>
<td>45%</td>
<td>13%</td>
</tr>
<tr>
<td>1 Other</td>
<td>4%</td>
<td>1%</td>
<td>4%</td>
<td>19%</td>
<td>4%</td>
<td>28%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>75%</td>
<td>7%</td>
<td>98%</td>
<td>39%</td>
<td>56%</td>
<td>53%</td>
<td>49%</td>
</tr>
<tr>
<td>2</td>
<td>6%</td>
<td>4%</td>
<td>-</td>
<td>4%</td>
<td>5%</td>
<td>45%</td>
<td>4%</td>
</tr>
<tr>
<td>3</td>
<td>19%</td>
<td>79%</td>
<td>1%</td>
<td>5%</td>
<td>38%</td>
<td>1%</td>
<td>17%</td>
</tr>
<tr>
<td>4</td>
<td>-</td>
<td>2%</td>
<td>1%</td>
<td>53%</td>
<td>1%</td>
<td>0%</td>
<td>30%</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1%</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>8%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diagnosed (Viremic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cases</td>
<td>5000</td>
<td>1050000</td>
<td>90000</td>
<td>20100</td>
<td>3300</td>
<td>93600</td>
<td>3600</td>
</tr>
<tr>
<td>Annual Newly Diagnosed</td>
<td>500</td>
<td>100000</td>
<td>7500</td>
<td>2000</td>
<td>170</td>
<td>8000</td>
<td>360</td>
</tr>
<tr>
<td>Treated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Number Treated</td>
<td>450</td>
<td>85000</td>
<td>41000</td>
<td>1900</td>
<td>150</td>
<td>4500</td>
<td>140</td>
</tr>
<tr>
<td>Liver Transplants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Liver Transplants</td>
<td>12</td>
<td>300</td>
<td>124</td>
<td>146</td>
<td>31</td>
<td>1212</td>
<td>20</td>
</tr>
<tr>
<td>HCV Liver Transplants</td>
<td>5</td>
<td>225</td>
<td>33</td>
<td>72</td>
<td>2</td>
<td>59</td>
<td>12</td>
</tr>
<tr>
<td>% due to HCV</td>
<td>40%</td>
<td>75%</td>
<td>27%</td>
<td>49%</td>
<td>7%</td>
<td>5%</td>
<td>60%</td>
</tr>
</tbody>
</table>

HCV antibody prevalence – prevalence of past or active HCV infection, viraemic prevalence – prevalence of active HCV infections, viraemic rate – percentage of past or active infections who have an active infection, viraemic-diagnosed individuals – the number of individuals diagnosed with an active infection, annual newly diagnosed – the number of active HCV infections diagnosed for the first time.
Fig. 1 Viraemic hepatitis C virus (HCV) prevalence by age and gender.
distribution of the prevalent population was estimated using unpublished laboratory data from 494 cases in Iceland collected by the Department of Virology at Landspitali University Hospital, while the distribution of G1 subtypes was based on data from the same source during an earlier time period.

**Diagnosed**

The total number of anti-HCV diagnosed cases is estimated at 1230, with 865 diagnosed after adjustment for mortality, viraemia and treated and cured. The newly diagnosed population in 2013 was estimated at 70, with approximately 60 newly diagnosed after adjustment for viraemia.

**Treated**

It was estimated that 25–30 patients were treated annually based on overall treatment levels between 2002 and 2012, during which a total of 207 patients received treatment.

**Liver transplants**

From 1985 to 2013, a total of 45 patients underwent liver transplantation in Iceland. Two transplants during this time period were attributable to HCV (4%).

**Indonesia**

**HCV-infected population**

The 2007 anti-HCV prevalence was estimated to be 0.8% (range 0.1% in Sumatra Barat to 1.7% in Nanggroe Aceh Darussalam), using the National Basic Health Research (RISKESDAS) 2007 study [21]. The viraemic rate was estimated to be 66% based on an older study [22]; however, this estimate is in line with more recent unpublished estimates (expert consensus). This corresponds to a viraemic prevalence of 0.5% (0.1–1.1%) in 2007, or 1,214,000 (182,000–2,534,000) infected individuals. The age and gender distribution was estimated using data from RISKESDAS 2007 [21]; however, it is important to note that the data are from the West and middle of Indonesia and are not necessarily representative of the entire country. Genotype 1 predominates in Indonesia, followed by G3. The genotype distribution (G1: 68%, G2: 9%, G3: 9%, G4: 4%, G other: 10%) was determined by averaging genotypes from three unpublished data sources, including a study in HIV-coinfected patients to account for under-represented populations (Lesmana, Muljono and Yunihastuti 2015 personal communications).
Diagnosed
Based on Indonesian Red Cross data and expert consensus, there were estimated to be 121,000 viraemic individuals (approximately 10% of the viraemic-prevalent population) with a known diagnosis of chronic HCV in 2013. Between 2007 and 2009, the Ministry of Health reported approximately 18,000 individuals diagnosed with HCV. Applying this annual number of diagnosed cases to the years 1992–2007 would suggest that by 2009 a total of 90,000 anti-HCV or 59,100 viraemic-diagnosed individuals and notified over five years (Syafitri 2015 personal communication). Overall, this suggests a total of 94,600 diagnosed and reported viraemic cases. Considering that some diagnosed cases would not be reported to the Ministry of Health or via blood donation, an overall diagnosis rate of 10% was estimated at approximately three times the number of known diagnosed cases. Approximately 12,100 viraemic cases were newly diagnosed annually, based on an estimate of 11,000 known cases and assuming a small number of unreported cases.

Treated
It was estimated that 230 patients were treated annually based on IMS data for standard units of Peg-IFN sold after adjustment to account for under-reporting and increased treatment of genotype 2 patients.

Liver transplants
Liver transplants are uncommon in Indonesia, as many patients travel abroad for a transplant. In one large hospital in Jakarta, there have been a total of 13 liver transplants performed (Gani 2015 personal communication). None of the patients treated were infected with HCV (Gani 2015 personal communication).

Iran
HCV-infected population
In 2006, a population-based study across three provinces estimated the antibody prevalence of HCV in adults aged 18–65 to be 0.5% [23]. When adjusted to include all ages, the anti-HCV prevalence in Iran is estimated to be 0.4% (0.3–0.5%), representing 275,000 (189,000–360,000) individuals in 2006. Utilizing a widely published viraemic rate of 62%, there is a viraemic prevalence of 0.2% (0.2–0.3%) representing approximately 170,000 (117,000–223,000) viraemic persons in 2006 [24]. The population-based study provided a reliable age and gender distribution [23]. Where data were lacking for the age and gender distribution, expert consensus was utilized. In Iran, the dominant genotype is 1, followed by genotype 3 [25].

Diagnosed
Based on expert opinion, it was estimated that there are 60,000 individuals diagnosed with HCV in Iran in 2013. It is estimated that there are 6000 individuals newly diagnosed annually.

Treated
Through expert consensus, it was estimated that there were 4500 individuals treated for HCV in 2011.

Liver transplants
Actual liver transplant data were available through IRO-DaT, with 590 liver transplants occurring in 2013. In Iran, 16% of all liver transplants are due to HCV, corresponding to 94 HCV-related liver transplants in 2013 [26].

Japan
HCV-infected population
The viraemic-prevalent population in 2011 was estimated to range from 1,010,000 to 1,510,000 individuals (equivalent to a viraemic prevalence of 0.8–1.2%). Based on ratios between base, high and low viraemic prevalence reported for 2005 [27], the base viraemic prevalence in 2011 was estimated at 1.0% (1,252,000 cases). With a viraemic rate of 70% [28], anti-HCV prevalence in 2011 was estimated at 1.4% (1,789,000 cases). The age and gender distribution of the infected population in 2005 was based on reported prevalence rates among individuals aged 5–74 years [27]. It was assumed that prevalence in the 0–4 year age group was equal to that of 5- to 9-year-olds. Prevalence among individuals aged 75+ years was assumed to increase as compared to younger individuals based on a trend of increasing prevalence with age. A male/female ratio of 0.96 was applied based on reported prevalence rates by gender [28]. The genotype distribution of the prevalent population was estimated using laboratory data from 494 cases in Japan, while the distribution of G1 subtypes was based on data from the same source during an earlier time period.

Diagnosed
The total number of viraemic undiagnosed cases was estimated at 296,000 cases in 2011 [27]. With 1,252,000 viraemic cases in 2011, the previously diagnosed viraemic population was estimated at 956,000. Based on expert consensus, the newly diagnosed viraemic population in 2014 is estimated at 8000.

Treated
Based on IMS unit for Peg-IFN sold in 2012, it was estimated that 26,900 patients were treated annually.

Liver transplants
Total annual liver transplants from 1989 to 2011 were reported by the Japanese Liver Transplantation Society.
The proportion attributable to HCV varied by year and ranged from 0% to 54%. In 2011, there were an estimated 219 liver transplants attributable to HCV.

Latvia

HCV-infected population

A 2008 population-based study in Latvia identified an anti-HCV prevalence of 2.4% (95% CI 1.7–3.3%) in the general population [30]. These data also suggest a viraemic rate of 71%, corresponding to a 1.8% (1.2–2.4%) viraemic prevalence in the total population (39 000 in 2008) [30]. The age and gender distribution was estimated using annual notification data from 2010 to 2014 (partial year 2014) [31]. The notified populations was aged to the year 2013, accounting for mortality and cured patients.

Diagnosed

As of 2008, approximately 17 000 of the 39 000 viraemic cases were diagnosed (42.5%) [32]. From 2010 to 2014, an average of 1300 chronic HCV cases were newly diagnosed [33].

Treated

In 2014, approximately 840 patients were treated for HCV with Peg-IFN and RBV. The number of patients treated annually between 2011 and 2014 was available from the National Health Service [34]. Additionally, the number of patients treated annually at the Infectology Center of Latvia was available for 2005–2014 (Tolmane 2015 personal communication).

Liver transplants

Liver transplants are not reimbursed by the government, and there has only been one liver transplant ever conducted in Latvia [20,32]. A long waiting list exists for transplants, and some patients (including children) have chosen to travel abroad for the procedure (expert consensus).

Lebanon

HCV-infected population

The most up-to-date data from 2010 to 2011 report an anti-HCV prevalence of 0.2% among all ages in the general population in Lebanon [35]. Low (0.1%) and high (0.7%) prevalence estimates were chosen from the literature [36,37]. A viraemic prevalence of 0.2% (0.1–0.6%) was calculated using the viraemic rate of 85% from the same study [35], corresponding with 7900 (2800–28 000) viraemic cases in 2011. The general population study was used to apply an age distribution and male-to-female ratio [35]. Unpublished data on 1030 HCV-infected patients from 2012 to 2013 determined the genotype distribution between genotypes 1 and 4, but the G1 subtype distribution came from a 2007 study [38].

Diagnosed

Data on number of HCV cases diagnosed in Lebanon are sparse. The Ministry of Health reports incomplete data, and there is no published literature on the annual number of diagnosed cases. Experts estimated that approximately 20% of all viraemic cases have been diagnosed, with 2% of viraemic cases diagnosed each year. This corresponds to approximately 1600 previously diagnosed cases and 160 newly diagnosed cases annually in 2014.

Treated

Data were obtained from the Ministry of Public Health on number of patients treated in 2013–2014, and expert input estimated this accounted for approximately 45% of all treated cases. Pharmaceutical audit data were used to estimate number treated from 2007 to 2012. It was estimated that 280 patients were treated in 2013 and 170 in 2014.

Liver transplants

Liver transplants are very rare in Lebanon. Data from the one hospital that performs transplants reported 15 transplants between 1999 and 2008, with only one due to HCV (6.7%) [39,40]. Experts estimate an additional 6–8 transplants were performed on Lebanese patients each year in foreign countries. Four transplants were performed and reported in Lebanon in 2013 [20].

Lithuania

HCV-infected population

A national seroprevalence survey was underway in Lithuania in 2010–2013. Although initial results from 2010 (anti-HCV prevalence of 2.85% among adults) have been published [41], there has been concern that the individuals seeking free testing in this first year were more likely to be at high risk of infection (Liakina 2015 personal communication). Preliminary results including 2010 and going through 2013 are currently unpublished but suggest an anti-HCV prevalence of 1.96% (1.21–2.71%) in adults 18–81 years of age (Liakina 2015 personal communication). When extrapolated to the entire population (all ages), an overall estimated anti-HCV prevalence of 1.7% (1.0–2.3%) was considered for 2013. These data also suggest a viraemic rate of 66%, corresponding to a 1.29% viraemic prevalence among adults 18–79 years, or 1.1% (0.7–1.5%) in the total population (33 000 in 2013) (Liakina 2015 personal communication). The age distribution was informed by initial 2010 results (5-year age-cohort) [41] and unpublished 2010–2013 results (average age of 47 ± 16 years) (Liakina 2015 personal communication). Approximately 54% of anti-HCV-positive individuals are male [41]. Of note, unpublished results suggest asymptomatic HCV-RNA carriers were younger (38.3 ± 15.5 years) and more evenly distributed by gender (52.6% males), as compared with the anti-HCV-positive population.
The 2003–2009 genotype distribution was estimated using data from 125 treatment naïve patients enrolled in the chronic hepatitis C cohort [42]. Additionally, the genotype 1a/1b split was available from 2000 patients admitted for antiviral treatment to the Center of Hepatology, Gastroenterology and Dietetics at Vilnius University Hospital Santariskiu Klinikos between 1996 and 2006 [43].

Diagnosed
Estimates of the diagnosed and newly diagnosed populations were unavailable, so the percentage of diagnosed cases in Poland (15%) in 2010 was chosen as an analogue, with 10% newly diagnosed annually (expert consensus). This corresponds to approximately 5000 total diagnosed and 500 annual newly diagnosed cases in 2010.

Treated
Accurate estimates of treated patients were not available; however, expert opinion suggested that between 300 and 600 patients have been treated annually since 2004 (Valantinas 2015 personal communication). The mid-point of 450 patients was chosen for the model.

Liver transplants
The annual number of liver transplants was available from IRODaT from 2002 to 2014 [20,44]. Of the 101 total liver transplants performed in Lithuania, 40 (40%) were attributable to HCV (Valantinas 2015 personal communication).

Pakistan
HCV-infected population
Pakistan has previously been identified as one of the three countries with the highest number of viraemic HCV infections in the world [45]. In 2008, there was a nationwide estimate on antibody prevalence of HCV infection corresponding to 4.8% [46]. A range of 3.5–5.9% was chosen by expert opinion. This rate corresponds to 8 010 000 (5 792 000–9 920 000) individuals infected with HCV in 2008. Utilizing a widely published viraemic rate of 87.4%, there is a viraemic prevalence of 4.2% (3.0–5.2%), representing approximately 7 001 000 (5 062 000–8 670 000) viraemic persons in 2008 [47]. The data from the aforementioned national study also provided a reliable age and gender distribution for the infected population. Data from a systematic review of 34 papers published between 1996 and 2011 were used to establish the genotype distribution [48].

Diagnosed
Based on expert opinion, it was estimated that 15% of the viraemic HCV-infected population had been diagnosed in 2010, corresponding to approximately 1 050 000 viraemic-diagnosed individuals. It is estimated that there are 100 000 individuals newly diagnosed annually.

Treated
It was estimated that there were 85 000 individuals treated in 2011. This was based on an analysis of standard and Peg-IFN units sold in Pakistan.

Liver transplants
Based on expert opinion, it is estimated that an annual 300 Pakistanis receive liver transplantation both domestically and abroad, with 75% of these transplants attributed to HCV [49,50].

Romania
HCV-infected population
The most recent HCV prevalence estimate in Romania was 3.23%, or 529 100 anti-HCV cases, among adults aged 18–69 in 2008 [51]. This estimate, applied to the entire population, increases to an anti-HCV prevalence of approximately 3.3%, or 719 000 cases. An anti-HCV prevalence range of 2.9–3.6% was chosen by expert input. A viraemic rate of 85% was determined by expert consensus, corresponding to a viraemic prevalence of 2.8% (2.5–3.1%) and 611 000 (541 000–680 000) viraemic cases in 2008. A nationwide study of the adult population determined the age distribution for 18- to 69-year-olds [51], and experts estimated that the prevalence rate would remain at the rate for 60- to 69-year-olds for adults over the age of 70. Based on expert consensus, the rates for the younger age groups (10–14, 5–9, 0–4) decreased by 25% with each successive age group. A genotype distribution study from 241 viraemic individuals from 2004 to 2008 found that the vast majority of cases were type 1b, followed by type 1a [52]. Only 1.20% of cases were found to be genotype 4, and 0.8% of cases were found to be genotype 3 [52].

Diagnosed
Based on expert consensus, there are an estimated 7500 viraemic cases diagnosed per year in Romania, and there have been an estimated 90 000 previously diagnosed cases.

Treated
In 2014, approximately 4100 new patients were treated in Romania, which is the lowest number of treatment initiations in the country since 2007 (Gheorghe 2015 personal communication). In 2013, for example, 6086 treatments were initiated (Gheorghe 2015 personal communication).

Liver transplants
Liver transplant data for 2000–2013 were available through the International Registry for Organ Donation and Transplantation and the Romania National Transplant Agency [20,44,53]. Expert consensus determined that the
number of liver transplants in 2014 was 124, a slight increase from the reported 122 transplants in 2013. Between 2000 and 2011, 27% of transplants in Romania were attributable to HCV [54].

Saudi Arabia

HCV-infected population

The prevalence rate of anti-HCV in Saudi nationals aged ≥15 years was estimated at 1.08% (0.97–1.19%) based on expert consensus, with a much lower prevalence rate among children (0.19%). Overall, the prevalence in Saudi nationals was estimated to be 0.7% (0.6–0.9%). A viraemic rate of 70% was applied [55], resulting in a viraemic prevalence rate of 0.5% (0.4–1.3%) among all ages and a total viraemic population of approximately 100 000 (81 000–257 000) individuals in 2011. The age distribution was based on data from 28 000+ blood units collected in a donor study conducted in the Jazan region from 2004 to 2009 [56] and then modified via expert input, specifically regarding ages >60 years. A male/female ratio based on a prevalence study of 1482 subjects in the Gizan area screened for HCV [57] was applied. Genotype distribution was applied from a meta-analysis of 18 genotype studies in Saudi Arabia [58] with genotype 1 subtype estimates provided by expert consensus.

Diagnosed

Data on the number of diagnosed HCV cases in Saudi Arabia are limited. The percentage of viraemic cases previously diagnosed was estimated at 20% in 2013 based on expert input. Cases newly diagnosed in 2013 were estimated to account for 10% of those previously diagnosed cases, or 3% of all viraemic cases. Thus, the total number diagnosed in 2013 was estimated to be 20 100 cases, with 2010 of those newly diagnosed that year.

Treated

It was estimated that 1900 Saudi nationals were treated annually in 2009 based on expert input and adjusting for immigrant patients. IMS data for standard units of Peg-IFN sold were used to estimate number treated from 2006 to 2009. The standard treatment in Saudi Arabia as of 2014 was Peg-IFN and ribavirin.

Liver transplants

In 2012, there were 146 liver transplants performed in Saudi Arabia according to data collected at a national organ transplantation centre from 1990 to 2012 [59]. It was estimated that 98% of these transplants were performed on Saudi nationals based on expert input. Nearly half of all liver transplants in Saudi Arabia were attributable to patients with HCV according to expert consensus.

Slovenia

HCV-infected population

The real HCV prevalence remains unknown in Slovenia as no national survey has been performed. HCV prevalence in the total population was estimated at 0.4% (0.3–0.5%) based on expert input. A study of 72% of all patients who were diagnosed with chronic HCV in Slovenia from 1993 to 2007 found a viraemic rate of 78% in 2007 [60], corresponding to a viraemic prevalence of 0.3% (0.2–0.4%), or 6500 (4900–8100) viraemic cases in 2014. The age and gender distribution was developed using data from the 1993–2007 study analysing 1504 serum samples (72.6% of all the patients diagnosed with hepatitis C in that period) that had been collected and processed on the national level at the referential laboratory for viral hepatitis of the Medical Faculty University of Ljubljana [60]. The highest rate of anti-HCV prevalence was found in 21- to 30-year-olds, and there was an overall ratio of 67.3% males to 32.7% females [60]. The genotype distribution of the infected population was also derived from the 1993–2007 study, with the majority of cases testing as genotypes 1 and 3 [60]. Ratios of genotype 1 subtypes 1a to 1b were determined using data from a study on pregnant women in Slovenia in 1993, 2003, 2009 and 2013 and were applied to the 1993–2007 genotype data [60,61].

Diagnosed

Expert consensus during a 2015 National Viral Hepatitis Expert Group panel in Slovenia estimated the number of previously diagnosed viraemic cases to be 3300 (Matičič 2015 personal communication). It is estimated that 5% of total diagnosed cases, or approximately 170 cases, are newly diagnosed each year.

Treated

HCV treatment in Slovenia is performed at five treatment centres in five regions of Slovenia, with the Clinic for Infectious Diseases and Febrile Illnesses at the University Medical Centre Ljubljana representing the referential centre. The National Viral Hepatitis Expert Group set up consensus guidelines for HCV treatment in 1997 and has been updating them regarding the Standard of Care [62]. The data on all the treated patients in Slovenia regarding treatment efficacy and safety have been collected and periodically analysed since 1997 [63,64]. The 2015 National Viral Hepatitis Expert Group panel came to the consensus that 1700 patients had already been treated as of March 2015 (Matičič 2015 personal communication). The number of treated patients in 2014 was estimated to be 150, based on expert input.

Liver transplants

Unpublished national liver transplant data between 1998 and 2014 from the National Viral Hepatitis Expert Group
indicate that approximately 7% of liver transplants during this period were attributable to HCV (Matić 2015 personal communication). In 2014, there were 31 liver transplants performed, an increase of 35% from the highest number of transplants performed in recent years (Matić 2015 personal communication).

South Korea

HCV-infected population
The most recent estimate of anti-HCV prevalence among adults was 1.2% in 2013, a slight reduction from 1.29% in 2009 [65]. This corresponds to 1.0% prevalence in the general population. Low (0.8%) and high (1.3%) prevalence estimates were chosen from the literature [65,66]. The viraemic rate was estimated to be 56%, corresponding to a viraemic prevalence of 0.6% (0.4–0.7%) in 2009 and 268 000 (211 000–349 000) infected individuals [66]. The age and gender distribution was estimated from a nationwide seroepidemiology survey of adults ≥20 years, in which the average age was 54 years [66]. For children and adolescents under 20 years of age, an accelerated reduction in prevalence was assumed. The genotype distribution was established from a study of 930 patients in the HCV cohort [67].

Diagnosed
As of 2012, approximately 93 600 viraemic cases were diagnosed (35%) (expert consensus). Annually, 8000 viraemic cases (3% of the total population) are newly diagnosed (expert consensus).

Treated
It was estimated that 4500 patients annually were treated based on expert consensus and IMS data for standard units of Peg-IFN sold after adjustment to account for under-reporting and increased treatment of genotype 2 patients.

Liver transplants
Liver transplant data for 2000–2011 were available through the Korean Network for Organ Sharing [68]. Prior to 2000, the number of transplants and percentage of transplants attributable to HCV (2.5%) were available through published estimates [69]. Indications for liver transplant were available from 2009 to 2013 through the Korean Network for Organ Sharing, which suggests that approximately 5% of liver transplants were attributable to HCV [68].

UAE

HCV-infected population
HCV epidemiology data are limited in the United Arab Emirates (UAE). Expert consensus estimates the prevalence of anti-HCV to be 1.5% (1.4–1.7%) among all ages of UAE nationals. A viraemic rate of 68% [70] was applied, resulting in a total viraemic population estimate of 11 000 (10 000 – 12 000) and a viraemic prevalence rate of 1.0% (0.9–1.1%) among UAE nationals. In the absence of data on age distribution, analogue data were used from 28 000+ blood units collected in a donor study conducted in Saudi Arabia from 2004 to 2009 to estimate the age distribution [71]. Based on expert input, age distribution was modified to peak around age 45 years and remained at a constant rate from that age forward. A male/female ratio was applied using unpublished data from Mafraq hospital in Abu Dhabi. Genotype distribution (including genotype 1 subtypes) was determined by aggregating data from a study of 124 UAE nationals in Dubai [72] and unpublished data from a hospital in Abu Dhabi and weighted by regional population.

Diagnosed
Expert consensus estimates that one-third of the viraemic population had been diagnosed in 2014. Using analogue data from Egypt, approximately 3% of viraemic cases were newly diagnosed in the same year [7]. It was estimated that a total of 3600 UAE citizens had been diagnosed as of 2014, including 360 newly diagnosed cases that year.

Treated
It was estimated that 140 patients were treated annually from 2011 based on expert consensus.

Liver transplants
Expert consensus approximates that around 30 liver transplants are performed each year with 20 of those performed on nationals. Experts estimate 60% of liver transplants are due to HCV.

DISCUSSION
This analysis was designed to develop consensus estimates for the epidemiology of HCV infection in the countries under study. Published data from each country were identified through an initial literature search. Those results were then discussed and reviewed with an expert advisory panel in each country. Where possible, the members of the advisory panel also provided additional data including hospital and national-level data as well as unpublished study data. This method of developing consensus estimates allowed for a more complete picture of HCV epidemiology to be developed, even in countries where national prevalence studies may not yet have been performed. In-depth review of all data with an advisory panel of experts in the field of HCV within each country also increased the accuracy of each analysis.

Given the substantial global disease burden associated with HCV, it is imperative that reliable epidemiological data are available so that policy makers can make the
most informed decisions possible for their respective countries. As higher efficacy treatments (SVR > 90%) with fewer side effects and shorter treatment durations become available, countries are faced with challenging public health policy questions about changing national treatment paradigms, such as the impact of limiting treatment to patients in certain disease stages. Data from this study can be used by researchers and policy makers to examine how best to combat HCV through further disease burden modelling, analysis of risk factors including the impact of immigration, and the creation of the most appropriate prevention, screening and treatment strategies.

Anti-HCV prevalence estimates in the countries represented in this study range from as low as 0.2% of the population in Lebanon to 4.8% in Pakistan. Figure 1 shows the age and gender distribution of HCV prevalence in each country. Examining the distribution in this manner allows for an analysis of the main risk factors associated with HCV infection. Countries where injection drug use (IDU) is the main source of new HCV infections (e.g. Iceland, Iran and Slovenia) generally display a higher prevalence in men of younger age groups, whereas countries where infection was historically related to an unsafe blood supply or nosocomial transmission (e.g. Japan, Pakistan and South Korea) generally display a higher prevalence in older age groups. Genotype distribution also varied widely between countries. This heterogeneity in genotype distribution is observed even among the countries in one region, which mainly reflects differences in HCV epidemiology, modes of transmission and ethnic variability. For example, Genotype 1 is the most common genotype in Iran, while Genotype 3 is prominent in Pakistan and Genotype 4 is the most common genotype in Saudi Arabia. Overall, Genotype 1 is the most common, accounting for over 80% of cases in some countries. However, it is difficult to make comparisons of genotype, age and gender distributions across countries, as estimates from the literature span a period of over 20 years. Comparison of HCV epidemiology across all countries in 2014 is the subject of another paper in this supplement [13].

Although a prevalence estimate was gathered for every country, the quality of estimates varied. A quantitative scoring system [73] was not used to compare the quality of prevalence figures, but national surveillance and general population studies in Indonesia, Latvia, Lebanon, Lithuania, Pakistan and Romania were more robust than consensus estimates. While the development of consensus estimates provides the best estimates of HCV epidemiology through the combination of all available data and expertise within a specific country, this method also has the potential for some biases. In countries where limited or no data were available, the estimates used in this analysis were based on the consensus of the advisory panel and therefore may not accurately represent the actual HCV epidemic in the country.

Furthermore, data used from registries or specific epidemiological studies may introduce a selection bias to this analysis, as testing and reporting may not be consistent across all subpopulations and would likely not be representative of hard-to-sample populations such as IDU.

It is important to note that the viraemic rate and genotype distributions often came from studies with small sample sizes, and in many countries, the genotype distribution is rapidly changing due to differences in historical risk factors compared to the risk factors currently driving the epidemic.

When data were not available for the number of treated patients within a country, estimates were based on drug sales data. In the absence of better information, the estimated number of treated patients by genotype was determined using the genotype distribution of the infected population. In some cases, these estimates still might be over- or under-estimates of the true treatment numbers genotype as some genotypes may be preferentially treated.

While this analysis is based on the best available data, the limitations inherent in these consensus estimates underscores the need for additional research to be conducted to further estimate the true HCV burden among both the general population and specific subpopulations who might be missed in a national study.

ACKNOWLEDGEMENTS

This project was supported by Gilead Sciences. The study of HCV disease burden in Iran was supported by the Center for Disease Analysis.

AUTHOR DISCLOSURES

V. Liakina has no conflict of interests to declare. S. Hamid has no conflict of interests to declare. J. Tanaka has received funding from AbbVie, Bristol-Myers Squibb, Chu- gai, Eisai, Gilead Sciences, Janssen, Otsuka and Sysmex. S. Olafsson has no conflict of interests to declare. K. Razavi-Shearer, J.D. Schmelzer, A. Sibley and J. Gunter have no conflict of interests to declare. I. Altraif has received support from Roche, Merck/MSD, Janssen, AbbVie and Bristol-Myers Squibb. S. Blach, C. Estes, H. Razavi, D. Razavi-Shearer, K. Razavi-Shearer, J.D. Schmelzer, A. Sibley and J. Gunter have no conflict of interests. They are employees of The Center for Disease Analysis and are barred from accepting remuneration. The Center for Disease Analysis has received research funding from public and private sources (Gilead Sciences, Boehringer Ingelheim and AbbVie), but its projects are limited to basic epidemiology and modelling research. F.Z. Alfaleh has received research grants from
REFERENCES


19. Sarvari C, Ujheely E, Szávák J et al. Determination of hepatitis C virus genotypes in Hungary using the


44 IRODaT. International Registry on Organ Donation and Transplantation. 7-9-2014. Barcelona, Spain, IRODaT. 3-1-2014.


49 Roghay S. 500th Pakistani to get liver transplant in India returns home. The News 2014 Apr 25.

50 Shifa International Hospitals Ltd. Liver Transplant. 2013.


© 2015 John Wiley & Sons Ltd